Stockreport

Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer

Guardant Health, Inc.  (GH) 
Last guardant health, inc. earnings: 2/24 04:03 pm Check Earnings Report
PDF REDWOOD CITY, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical ou [Read more]